Hansoh Pharma’s Ameile Approved for Fourth Use in EGFR+ NSCLC Adjuvant Therapy
Hansoh Pharma’s Ameile Gains Approval for New Indication in Early-Stage EGFR-Mutant NSCLC Hansoh Pharmaceutical Group Co., Ltd (03692.HK), hereafter referred to as Hansoh Pharma, announced that its innovative product Ameile…
Icotrokinra Shows Strong Results in Hard-to-Treat Scalp and Genital Psoriasis
Johnson & Johnson (NYSE: JNJ) today announced promising new results from the Phase 3 ICONIC-TOTAL study evaluating icotrokinra (JNJ-2113), a first-in-class investigational targeted oral peptide designed to selectively block the…
Lilly to Invest $250M in Purdue Partnership for Pharma Innovation
Eli Lilly and Purdue University Announce Landmark $250 Million Research Collaboration Eli Lilly and Company (NYSE: LLY) and Purdue University today unveiled a major expansion of their long-standing partnership, with…
Viatris Reports Positive Phase 3 Results for XULANE LO™ Low-Dose Birth Control Patch
A global healthcare company today announced positive top-line results from its Phase 3 clinical trial (NCT05139121) evaluating the contraceptive efficacy and safety of XULANE LO, an investigational low-dose weekly transdermal…
Lupin Secures FDA Nod for 600 mg Raltegravir Tablets USP
Global pharmaceutical major Lupin Limited announced today that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) for…
Imfinzi Shows Significant Disease-Free Survival Benefit in High-Risk NMIBC: POTOMAC Phase III Trial
AstraZeneca announced promising top-line results from its Phase III POTOMAC trial, showing that one year of treatment with Imfinzi (durvalumab) combined with standard-of-care Bacillus Calmette-Guérin (BCG) induction and maintenance therapy…
Shionogi, Partners Join to Boost Antimicrobial Stewardship in Kenya
Shionogi Forms Comprehensive Partnership to Strengthen Antimicrobial Stewardship in Kenya Shionogi & Co., Ltd. (Head Office: Chuo-ku, Osaka; “Shionogi”) is pleased to announce that it has signed a comprehensive partnership…
GLISTEN Phase III: Linerixibat Significantly Eases Itch in PBC
GSK Reports Positive Phase III Results for Linerixibat in Treating Itch Associated with PBC GSK plc (LSE/NYSE: GSK) today announced positive results from its GLISTEN phase III trial evaluating linerixibat,…
Merck and Kansas Announce $895M Investment in De Soto Facilities
Merck Animal Health and State of Kansas Announce $895 Million Investment in De Soto Manufacturing and R&D Facilities Merck Animal Health launches its largest economic development project to date Rahway,…
Johnson & Johnson Increases Global Efforts to Champion Nurses
Johnson & Johnson Expands Global Commitment to Strengthen Nursing Workforce and Improve Healthcare Access Johnson & Johnson today announced the expansion of its efforts to champion the nursing workforce and…
Lilly Announces Executive Leadership Changes
Eli Lilly Announces Executive Leadership Changes to Propel Future Growth Eli Lilly and Company (NYSE: LLY) today announced a series of executive leadership transitions designed to strengthen its ability to…
Teva to Host Innovation and Strategy Day on May 29 in New York City
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) stands as a unique global biopharmaceutical leader, delivering a wide range of medicines to patients around the world. With a legacy spanning…